Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: Acute and six month outcomes

H. B. Solvason, M. Husain, P. B. Fitzgerald, Peter B. Rosenquist, William Vaughn McCall, J. Kimball, W. Gilmer, M. A. Demitrack, S. H. Lisanby

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background Transcranial magnetic stimulation (TMS) is a safe and effective treatment for major depression. We describe quality of life (QOL) outcomes from acute treatment with TMS, and describe the durability of benefit across 24-weeks. Methods Three hundred and one medication-free patients with pharmacoresistant major depression were randomized to active or sham TMS in a 6-week controlled trial. Nonresponders to the 6-week blinded phase of the study were enrolled in a 6-week open-label study without unblinding the prior treatment assignment. Responders and partial responders to both the blinded (active or sham treatment) or open acute treatment phases were tapered off TMS over three weeks, while initiating maintenance antidepressant medication monotherapy. These subjects entered the 24-week study to examine the durability of response to TMS. The Medical Outcomes Study-36 Item Short Form (SF-36) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used to measure overall function and QOL. During the 24-week durability of effect study, QOL assessments were done at study entry and at the end of 24-weeks. Results Statistically significant improvement in both functional status and QOL outcomes was observed in patients treated with active TMS compared with sham TMS during the acute phase of the randomized, sham-controlled trial. Similar benefits were observed in patients who entered the open-label extension study. These improvements were sustained across the 24-week follow up study. Conclusions Acute treatment with TMS improved functional status and QOL outcomes in patients with major depression. This clinical effect was durable in long-term follow up.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalBrain Stimulation
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Transcranial Magnetic Stimulation
Quality of Life
Depression
Therapeutics
Antidepressive Agents
Randomized Controlled Trials
Placebos
Maintenance
Outcome Assessment (Health Care)

Keywords

  • Antidepressant
  • Clinical trial
  • Major depression
  • Quality of life
  • TMS
  • Treatment resistance

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Biophysics
  • Medicine(all)

Cite this

Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression : Acute and six month outcomes. / Solvason, H. B.; Husain, M.; Fitzgerald, P. B.; Rosenquist, Peter B.; McCall, William Vaughn; Kimball, J.; Gilmer, W.; Demitrack, M. A.; Lisanby, S. H.

In: Brain Stimulation, Vol. 7, No. 2, 01.01.2014, p. 219-225.

Research output: Contribution to journalArticle

Solvason, H. B. ; Husain, M. ; Fitzgerald, P. B. ; Rosenquist, Peter B. ; McCall, William Vaughn ; Kimball, J. ; Gilmer, W. ; Demitrack, M. A. ; Lisanby, S. H. / Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression : Acute and six month outcomes. In: Brain Stimulation. 2014 ; Vol. 7, No. 2. pp. 219-225.
@article{e036d1e70f994f9983a4442e6999f748,
title = "Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: Acute and six month outcomes",
abstract = "Background Transcranial magnetic stimulation (TMS) is a safe and effective treatment for major depression. We describe quality of life (QOL) outcomes from acute treatment with TMS, and describe the durability of benefit across 24-weeks. Methods Three hundred and one medication-free patients with pharmacoresistant major depression were randomized to active or sham TMS in a 6-week controlled trial. Nonresponders to the 6-week blinded phase of the study were enrolled in a 6-week open-label study without unblinding the prior treatment assignment. Responders and partial responders to both the blinded (active or sham treatment) or open acute treatment phases were tapered off TMS over three weeks, while initiating maintenance antidepressant medication monotherapy. These subjects entered the 24-week study to examine the durability of response to TMS. The Medical Outcomes Study-36 Item Short Form (SF-36) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used to measure overall function and QOL. During the 24-week durability of effect study, QOL assessments were done at study entry and at the end of 24-weeks. Results Statistically significant improvement in both functional status and QOL outcomes was observed in patients treated with active TMS compared with sham TMS during the acute phase of the randomized, sham-controlled trial. Similar benefits were observed in patients who entered the open-label extension study. These improvements were sustained across the 24-week follow up study. Conclusions Acute treatment with TMS improved functional status and QOL outcomes in patients with major depression. This clinical effect was durable in long-term follow up.",
keywords = "Antidepressant, Clinical trial, Major depression, Quality of life, TMS, Treatment resistance",
author = "Solvason, {H. B.} and M. Husain and Fitzgerald, {P. B.} and Rosenquist, {Peter B.} and McCall, {William Vaughn} and J. Kimball and W. Gilmer and Demitrack, {M. A.} and Lisanby, {S. H.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.brs.2013.10.008",
language = "English (US)",
volume = "7",
pages = "219--225",
journal = "Brain Stimulation",
issn = "1935-861X",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression

T2 - Acute and six month outcomes

AU - Solvason, H. B.

AU - Husain, M.

AU - Fitzgerald, P. B.

AU - Rosenquist, Peter B.

AU - McCall, William Vaughn

AU - Kimball, J.

AU - Gilmer, W.

AU - Demitrack, M. A.

AU - Lisanby, S. H.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background Transcranial magnetic stimulation (TMS) is a safe and effective treatment for major depression. We describe quality of life (QOL) outcomes from acute treatment with TMS, and describe the durability of benefit across 24-weeks. Methods Three hundred and one medication-free patients with pharmacoresistant major depression were randomized to active or sham TMS in a 6-week controlled trial. Nonresponders to the 6-week blinded phase of the study were enrolled in a 6-week open-label study without unblinding the prior treatment assignment. Responders and partial responders to both the blinded (active or sham treatment) or open acute treatment phases were tapered off TMS over three weeks, while initiating maintenance antidepressant medication monotherapy. These subjects entered the 24-week study to examine the durability of response to TMS. The Medical Outcomes Study-36 Item Short Form (SF-36) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used to measure overall function and QOL. During the 24-week durability of effect study, QOL assessments were done at study entry and at the end of 24-weeks. Results Statistically significant improvement in both functional status and QOL outcomes was observed in patients treated with active TMS compared with sham TMS during the acute phase of the randomized, sham-controlled trial. Similar benefits were observed in patients who entered the open-label extension study. These improvements were sustained across the 24-week follow up study. Conclusions Acute treatment with TMS improved functional status and QOL outcomes in patients with major depression. This clinical effect was durable in long-term follow up.

AB - Background Transcranial magnetic stimulation (TMS) is a safe and effective treatment for major depression. We describe quality of life (QOL) outcomes from acute treatment with TMS, and describe the durability of benefit across 24-weeks. Methods Three hundred and one medication-free patients with pharmacoresistant major depression were randomized to active or sham TMS in a 6-week controlled trial. Nonresponders to the 6-week blinded phase of the study were enrolled in a 6-week open-label study without unblinding the prior treatment assignment. Responders and partial responders to both the blinded (active or sham treatment) or open acute treatment phases were tapered off TMS over three weeks, while initiating maintenance antidepressant medication monotherapy. These subjects entered the 24-week study to examine the durability of response to TMS. The Medical Outcomes Study-36 Item Short Form (SF-36) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used to measure overall function and QOL. During the 24-week durability of effect study, QOL assessments were done at study entry and at the end of 24-weeks. Results Statistically significant improvement in both functional status and QOL outcomes was observed in patients treated with active TMS compared with sham TMS during the acute phase of the randomized, sham-controlled trial. Similar benefits were observed in patients who entered the open-label extension study. These improvements were sustained across the 24-week follow up study. Conclusions Acute treatment with TMS improved functional status and QOL outcomes in patients with major depression. This clinical effect was durable in long-term follow up.

KW - Antidepressant

KW - Clinical trial

KW - Major depression

KW - Quality of life

KW - TMS

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=84896388497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896388497&partnerID=8YFLogxK

U2 - 10.1016/j.brs.2013.10.008

DO - 10.1016/j.brs.2013.10.008

M3 - Article

C2 - 24332384

AN - SCOPUS:84896388497

VL - 7

SP - 219

EP - 225

JO - Brain Stimulation

JF - Brain Stimulation

SN - 1935-861X

IS - 2

ER -